DAIICHI SANKYO GROUP, a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the group has since achieved significant milestones, including advancements in oncology and cardiovascular treatments. Specialising in innovative medicines, DAIICHI SANKYO is renowned for its unique drug development capabilities, particularly in targeted therapies and biologics. The company’s commitment to research and development has positioned it as a leader in the pharmaceutical market, with notable achievements such as the successful launch of several blockbuster drugs. With a strong focus on improving patient outcomes, DAIICHI SANKYO continues to make strides in the healthcare sector, solidifying its reputation as a trusted name in pharmaceuticals.
How does DAIICHI SANKYO GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
DAIICHI SANKYO GROUP's score of 58 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, DAIICHI SANKYO GROUP reported total greenhouse gas emissions of approximately 4,460,241,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 85,245,000 kg CO2e, while Scope 2 emissions totalled approximately 23,994,000 kg CO2e. The majority of emissions stemmed from Scope 3, particularly from purchased goods and services, which accounted for about 4,430,241,000 kg CO2e. DAIICHI SANKYO has set ambitious climate commitments, aiming for a 63% reduction in absolute Scope 1 and Scope 2 emissions by FY2030, using FY2015 as the baseline. Additionally, the company is committed to achieving net-zero greenhouse gas emissions by FY2050 and plans to increase its sourcing of renewable electricity from 4% in FY2015 to 100% by FY2030. Furthermore, DAIICHI SANKYO aims for 70.6% of its suppliers, based on emissions, to establish science-based targets by FY2025. In the near term, the company has also committed to a 42% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2023 base year, while actively measuring and reducing its Scope 3 emissions. These initiatives reflect DAIICHI SANKYO's dedication to addressing climate change and aligning with global sustainability goals.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Scope 1 | 86,785,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 96,080,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 609,954,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DAIICHI SANKYO GROUP is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.